Cat drug PURR-001 shows positive clinical results and lands Vetro licensing deal

The Cat Health Company said its once-weekly oral therapy PURR-001 improved muscle and body mass in a 35-cat European study and has been licensed to Vetro Solutions for manufacturing and regulatory work. The results could accelerate development of a first-in-class treatment for age-related muscle loss in cats.

Why it matters: - Age-related muscle loss in cats has no approved drug, leaving a large untreated market in aging companion animals. - The company says 41 million geriatric cats over age 10 live across the US and EU. - Positive clinical data and a manufacturing deal could move PURR-001 closer to broader commercialization.

What happened: - The Cat Health Company announced positive clinical results for PURR-001, a once-weekly oral therapeutic for age-related muscle loss in cats. - A state-supervised, placebo-controlled, double-blind, multi-site clinical trial in Europe enrolled 35 geriatric cats. - The company also said it signed its first European out-licensing contract with Vetro Solutions.

The details: - Cats receiving PURR-001 gained an average of 7% in body mass over 12 weeks, compared with 1% in the placebo group. - Investigators used ultrasound to measure epaxial muscle thickness. - Epaxial muscle thickness increased an average of 23% in treated cats versus 9% on placebo. - Across the study population, epaxial thickness explained 48% of the variance in body mass. - Hematology and serum biochemistry stayed within normal limits at weeks 0, 6 and 12. - Adverse events occurred at similar rates in both study arms. - Full results, safety data and methods are available in a preprint. - Under the licensing agreement, Vetro Solutions will handle industrial-scale manufacturing, regulatory dossier preparation and regional distribution. - Financial terms were not disclosed. - Commercial infrastructure now covers seven major European markets, with letters of intent in place for additional territories outside Europe. - The Cat Health Company said it has retained full U.S. and international commercialization rights and plans to assign them in coming quarters. - PURR-001 is the first clinical-stage therapeutic from The Cat Health Company’s computational drug-development engine. - The program moved from start to a European manufacturing and distribution deal in less than two years. - PURR-001 has not received marketing authorization in any territory and is not available by prescription.

Between the lines: - The Vetro deal shifts development burden away from The Cat Health Company and onto a partner with veterinary manufacturing and regulatory experience. - The structure suggests the company wants to focus internal resources on pipeline expansion rather than building commercial infrastructure itself. - Alex Bacita, COO and co-founder, framed the opportunity as broader than muscle loss, pointing to more age-related diseases in cats. - Alex Voda, CEO and co-founder, said the partnership will let the company spend more time on next-generation drugs.

What's next: - The Cat Health Company said it will develop and publish science on additional aging targets in cats, including chronic kidney disease, neuronal disease and cardiovascular disease. - The company also plans a U.S. expansion with new office and laboratory space. - The company expects to announce collaborations with companies and scientists working on aging-related research worldwide. - Vetro Solutions will support the product’s path toward regulatory authorization and commercialization.

The bottom line: - PURR-001 has early clinical traction, and the Vetro partnership gives the program a clearer path from trial data to market preparation.